25

2025-06

Receipt Of JNCI Designation For KT-939

Suzhou, 25 June, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that its in-house developed KT-939 has passed the review of the Japanese Nomenclature Cosmetic Ingredient (the “JNCI”) by the Japanese Cosmetic Industry Committee. The officially assigned name is メチルオキセタンカルバミドチアゾリルレゾルシノ一ル. Such designation approval signifies that KT-939 may commence application and sales as a cosmetic raw material in Japan market, laying a material foundation for the Company’s expansion in the functional cosmetic raw material market, helping further promote the demand for products of the Company and driving the company to become a leading supplier of the functional cosmetic raw material.

13

2025-06

Exclusive Global 20 Seats, China's Sole One! KT-939 Was Successfully Selected for 2025 NYSCC Inspiration Hive Zone

SUZHOU, China, May 28, 2025 /PRNewswire/ -- In the newly announced entry list of the Inspiration Hive zone at the 2025 New York Society of Cosmetic Chemists (NYSCC) exhibition, Kintor's innovative ingredient KT-939 has been selected as the only "Chinese Ingredient" among the numerous global ones. It will compete with global industry giants such as Ashland, DSM-Firmenich, and Eastman, marking a groundbreaking milestone that China's cosmetic ingredient R&D stands at the forefront of global innovation.

23

2025-05

Exclusive Global 20 Seats, China’s Sole One! KT-939 Was Successfully Selected for 2025 NYSCC Inspiration Hive Zone

In the newly announced entry list of the Inspiration Hive zone at the 2025 New York Society of Cosmetic Chemists (NYSCC) exhibition, Kintor’s innovative ingredient KT-939 has been selected as the only "Chinese ingredient" among the numerous global ones. It will compete with global industry giants such as Ashland, DSM-Firmenich, and Eastman, marking a groundbreaking milestone that China’s cosmetic ingredient R&D stands at the forefront of global innovation.

08

2025-05

Official Commencement Of Global Sales Business Of Whitening And Freckle-Removing Functional Cosmetic Raw Material KT-939

Suzhou, 8 May, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the global sales business of its self-developed KT-939, a functional raw material for whitening and freckle-removing cosmetics, has officially commenced. The Company has recently completed its first sales of this raw material. This signifies that the Company has officially tapped into the functional cosmetic raw material industry with an aim to provide high-quality and safe cosmetic raw material for the global cosmetic market.

02

2025-05

Superior Efficacy Of Clinical Observational Study In Kx-826 In Combination With Minoxidil For The Treatment Of Male Adults With Aga In China Over Minoxidil Monotherapy

Suzhou, 2 May, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that a clinical observational study of KX-826 in combination with minoxidil for the treatment of male adults with AGA in China has reached the primary endpoint.

20

2025-03

Long-Term Safety Phase III Clinical Trial Of KX-826 For The Treatment Of AGA Reached Primary Endpoint

Suzhou, 20 March, 2025-Kintor Pharmaceutical Limited (“Kintor Pharma”, HKEX: 9939), announced that the long-term safety phase III clinical trial of its in-house developed and potential first-in-class KX-826 tincture for the treatment of AGA has obtained top-line results. Results indicated that the Long-term Safety Clinical Trial has reached its primary endpoint with statistically significant and clinically meaningful outcomes, demonstrating excellent safety and efficacy.

< 1234...25 > proceed page

Kintor